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Glucocorticoids are among the most prescribed drugs worldwide for the treatment of numerous immune and
inflammatory disorders. They exert their actions by binding to the glucocorticoid receptor (GR), a member of
the nuclear receptor superfamily. There are several GR isoforms resulting from alternative RNA splicing and
translation initiation of the GR transcript. Additionally, these isoforms are all subject to several transcriptional,
post-transcriptional, and post-translationalmodifications, all ofwhich affect the protein’s stability and/or func-
tion. In this review,we summarize recentknowledgeon thedistinctGR isoformsand theprocesses thatgenerate
them. We also review the importance of all known transcriptional, post-transcriptional, and post-translational
modifications, includingthe regulationofGRbymicroRNAs.Moreover,wediscuss thecrucial roleof theputative
GR-bound DNA sequence as an allosteric ligand influencing GR structure and activity. Finally, we describe how
the differential composition and distinct regulation at multiple levels of different GR species could account for
the wide and diverse effects of glucocorticoids. (Endocrine Reviews 35: 671–693, 2014)
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I. Introduction
Glucocorticoids (GCs) are steroid hormones that areproduced by the adrenal cortex, under tight regu-
lation by the hypothalamic-pituitary-adrenal gland axis.
GCs are pivotal regulators of a wide variety of fundamen-
tal processes, such as metabolic homeostasis, cell prolif-
eration, inflammation, immune responses, development,
and reproduction (1–3). Because of their lipophilic nature,
GCs can readily diffuse across cellularmembranes to exert
their biological actions.
GCs function by binding to their intracellular receptor,
the GC receptor (GR), which is a ligand-inducible tran-
scription factor belonging to the nuclear receptor super-
family (4). In the absence of ligand, GR resides predom-
inantly in the cytoplasm within a multimeric chaperone
complex comprising heat-shock protein (hsp) 90, hsp70,
hsp90-binding protein p23, immunophilins (eg, FKBP51,
FKBP52,Cyp44, andPP5), and other factors to prevent its
degradation and assist in its maturation (5). Upon ligand
binding, the GR complex changes its conformation and
travels to the nucleus, where it interacts with coregulators
that assist GR transcriptional actions. The SRC family of
coactivators are well known to aid GR in its transcrip-
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tional activity, but viral components, for example, have
alsobeendescribed to act as coactivators ofGR (6).On the
contrary, otherGR interactionpartners canact asnegative
regulators ofGC signaling. For instance, the interaction of
GR with 14–3–3 enhances GR nuclear export (7), bind-
ing to Fas associated protein with death domain-Like in-
terleukin-1 converting enzyme-AssociatedHuge protein
(FLASH) impairs GR transcriptional actions due to re-
duced availability of the GR interacting protein 1 coacti-
vator (8), and binding of GR with -units of G proteins
disrupts the transcriptional activation complex (9). Note
thatGR is not rigidly compartmentalized; a constant shut-
tling between nucleus and cytoplasm occurs with both
activated and nonactivated forms of GR (5, 10), a mech-
anism that allows the GR to dynamically act as a sensor.
GR is constitutively expressed in virtually every cell type,
but tissue-specific expression patterns of GR result in dif-
ferent transcriptional outcomes (11, 12).
In the nucleus, GR acts as a transcription factor, me-
diating the up- and down-regulation of numerous genes in
a coordinated fashion. Transcriptional induction of genes
by GR is mediated mainly by binding of GR dimers to
so-called GC response elements (GREs). Note that this
GR-mediated transcriptional profile is very cell type-spe-
cific, as was recently confirmed by several chromatin im-
munoprecipitation sequencing (ChIPseq) analyses in
which limited overlap in GR binding sites in different cell
types and tissues could be found (13–15). In addition to
the induction of genes encoding anti-inflammatory pro-
teins, such as Tsc22d3 (encoding GILZ) and Dusp1 (en-
codingMKP-1) (16), GR exerts part of its anti-inflamma-
tory effects by interacting with proinflammatory
transcription factors, such as nuclear factor B (NFB)
and activator protein-1 (AP-1), leading to the transcrip-
tional repression of many genes. In addition to ligand-
activated GR, a recent report shows gene expression
changes by the unliganded GR (17). Although most ac-
tivities of GR are performed in the nucleus, rapid non-
genomicGCactions alsooccur,which can indirectly affect
gene transcription, eg, by direct inactivation of MAPK or
phosphatidylinositol-3-kinase (18). Moreover, GCs can
intercalate into cellular membranes and alter the physio-
chemical properties of these membranes, as well as the
activities of membrane-associated proteins (19, 20). GR
itself canalso interactwith cellularmembranes, eg, amem-
brane-bound GR was identified as a component of the
T-cell receptor complex, negatively affecting downstream
signaling (21). Altogether, these mechanisms in part sup-
port the rapid anti-inflammatory effects of GCs (22).
In this review,we provide a state-of-the-art overviewof
the structure and regulation of GR.We discuss both tran-
scriptional and post-translational modifications. Further-
more, we highlight the importance of recently identified
micro-RNAs (miRs) in the regulation of GR production
and activity.Wealso focus on the key novel findings about
the allosteric aspect of the DNA sequence in directing GR
structure and transcriptional outcome.We emphasize that
the regulation of GR, and hence its entire signaling cas-
cade, is enormously complex, and that understanding this
advanced regulation is crucial for the development of
more effective GC therapies.
II. Regulation of GR Gene Expression
GR levels within the cell are not static but are tightly con-
trolled by numerous factors and at multiple levels. In eu-
karyotic cells, protein expression levels in general are pri-
marily determined by themRNA level. Gene expression is
firmly controlled by awide variety of mechanisms at tran-
scriptional, post-transcriptional, and post-translational
levels. Although GR is constitutively expressed, it shows
distinct expression patterns in different cells and tissues
due to differential regulation. Here, we describe the mul-
tilevel regulatorymechanisms, leading to its tissue-specific
expression profile. For a complete overview, see Figure 1.
A. Genomic Structure of GR
In humans, the GR gene (NR3C1) is located on the
short arm of chromosome 5 (5q31Y32) (23). This gene
comprises nine exons, of which exons 2 through 9 encode
the protein. So far, 13 variants of human GR (hGR) exon
1differing in the upstreampromoter regions (promotersA
through F andH through J) have been identified (Figure 1)
(24–28). Both promoters A and C regulate three distinct
untranslated exons (1A1–3, 1C1–3) owing to the unique
promoter fragments (25). The promoter region is long and
includes elements as far upstream as 35 kb. The location
of the different promoters was estimated based on the
presence of highly conserved regions and on literature
mining (25, 29). For example, the hGR1A promoter reg-
ulating transcription starting from exon 1C was found
about 27 kb upstream of that transcription start site (25).
The existence of these alternative promoters, each dis-
playing a distinct level of expression and tissue specificity,
illustrates the plasticity and complexity in hGR regulation
at the transcriptional level. The 5 untranslated region
(UTR) of hGR is very similar to the mouse and rat first
exons, at least in number and structure (24, 30).
B. Transcriptional control of the GR-coding gene NR3C1
The promoter region (5 UTR) of GR has been exten-
sively studied. It is very GC-rich (72% GC content) but
does not contain a TATA or a CAT box (29, 31). The
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major transcription start site is located in exon 2, 134 bp
upstreamof theATGinitiation codon (31).Thepromoters
comprise multiple binding sites for several known tran-
scription factors: AP-1 (29, 32), AP-2 (33), NFB (34),
estrogen receptor (29, 35), cAMP response element bind-
ing protein (29), NF1/CTF1 (29), Yin Yang 1 (36), Sp1
(27, 33, 36), IRF1/2 (25, 37), cMyb (38, 39), PU.1 (38,
39), and EGR1/NGF1-A (40–42). Whereas the above-
mentioned transcription factors are known to up-regulate
GR expression, GC responsive factor-1 (43, 44) and c-Ets-
1/2 (38) have been shown to repress GR expression. Note
that small noncoding“tinyRNAs”might alsobe involved in
thetranscriptionalregulationofGRbecausetheseRNAmol-
ecules can turn off target gene expression bybinding to com-
plementary regions in promoter DNA (45). However, this
hypothesis needs further investigation and validation.
Moreover, multiple GREs and negative GREs (nGREs)
have been identified in the promoter region of GR (46).
This implies that GR can specifically bind to its own pro-
moter. Several GRE half-sites act in concert with other
transcription factors, such as cMyb and c-Ets-1/2 (38). In
the presence of cMyb, the GC-activatedGR is recruited to
the promoter of its own gene and up-regulates its own
expression. The interaction ofGRwith familymembers of
the c-Ets family leads to repression of GR expression (38,
39). Additionally, a functional nGRE was recently iden-
tified in exon 6 of GR (47). This nGRE might contribute
to the ligand-dependent homologous down-regulation of
GR. Consequently, chronic administration of GCs can
constitutively repress GR expression via an autoregula-
tory loop and thereby induce GC resistance, ie, unrespon-
siveness to the beneficial anti-inflammatory effects of GR.
It is clear that the binding of different transcription factors
to the promoter region of the GR gene (NR3C1) can have
different effects. This could explain the tissue-specific ef-
fects ofGCs, but themechanisms atwork in this promoter
in different cell types are still far from clear. Moreover,
autocrine regulation of GR further complicates the un-
derstanding of GR biology.
C. Post-transcriptional regulation of the GR transcript
The stability of GR mRNA is controlled by various
mechanisms. The highly overrepresented presence of ad-
enylate uridylate (AU)-rich elements (AREs) in the 3UTR
of GR mRNA might mediate mRNA destabilization and
hence affectGRprotein expression (48, 49).However, the
Figure 1.
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Figure 1. Regulation of GR gene expression. A, Genomic structure of the hGR gene. B, hGR promoter region: transcription factor binding sites
are depicted in dark gray boxes and GC-rich regions in light gray boxes. C, hGR 3 UTR region: AU-rich elements are depicted in dark gray boxes
and miR target sites are indicated by the arrows.
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mechanisms and contributions of ARE-induced GR
mRNA degradation are not fully understood or experi-
mentally evaluated. One could make use of ARE data-
bases, such as AREsite and ARED 3.0, to search for ad-
ditional ARE sites and study them in silico (50, 51), but
such an endeavor has not been reported.
miRs present another level for fine-tuning GR levels.
Several reports have illustrated the importance of miRs in
controlling GR mRNA stability. miRs were discovered in
2001 (52, 53) and later predicted to regulate up to 30%of
all genes (54). Since then, various studies have led to the
conclusion that miRs account for about 1% of the entire
human genome and play critical roles in a wide variety of
cellular processes, such as inflammation, cell differentia-
tion, and apoptosis (55). miRs are single-stranded non-
coding RNAmolecules of about 21 nucleotides. They ex-
ert their functions by incomplete base pairing to sequence
motifs in their targetmRNAs,preferentially in the3UTR,
and in that way they interfere with mRNA stability and
translation (56). Potential miRs targeting the 3 UTR of
GR can be predicted using publicly available software
packages, such as Targetscan 4.2 and MiRwalk (57, 58).
These programs indicate that the 3 UTR of GR is indeed
under tight miR control. Moreover, several reports have
illustrated the targeting of the GR 3 UTR by miRs. For
example, amiRmicroarray analysis has identified adrenal
miRs that seem to target GR upon ACTH stimulation, of
which fourwere experimentally confirmed to target the 3
UTR of GR, namely miR-96, miR-101a, miR-142–3p,
and miR-433. These miRs can repress the GR expression
level to 40% (59). Because these miRs are up-regulated
uponACTH stimulation and subsequently repress GR ex-
pression levels, this could contribute to the GC-induced
autoregulation of GR. Furthermore, the decreased GR
level in human T-cell acute lymphoblastic leukemia could
point to an oncogenic role for miR-142–3p because the
GC-resistant condition could be reverted by a miR-
142–3p inhibitor (60). The above-mentioned microarray
analysis also identified another differentially expressed
miR, miR-18a (59). Interestingly, miR-18a has already
been shown to be increased in the paraventricular nucleus
of rats, where itmediates the down-regulation ofGR (61).
Furthermore, the importanceofGRregulationbymiR-18,
which is widely expressed throughout the body, has also
been illustrated by Vreugdenhil et al (62). miR-124a,
which is predominantly expressed in the brain, was also
shown to down-regulate GR expression. Both miRs bind
to the 3 UTR of GR, and in that way they mediate the
down-regulationofGR,which leads toattenuationofGR-
mediated transcriptional induction (62). Another report
has linked the expression of miR-124 to the subsequent
down-regulation of GR with acquired GC resistance in
sepsis patients. Furthermore, the expression of miR-124
was up-regulated by GC-induced stimulation of T cells.
This is another possible mechanism for the GC-induced
autoregulation of GR and acquisition of GC resistance in
sepsis. Actually, T cells of sepsis patients exhibit a slight
decrease in GR expression, correlating with slightly in-
creased miR-124 expression (63). Another recent report
indicates a critical role for miR-130b, miR-181a, and
miR-636 in regulating the GC response in multiple my-
eloma (64).
These findings suggest that miRs can, by post-tran-
scriptional regulation, affect the expression levels of GR
and its subsequent activity. Moreover, the modulation of
GR translation activity by miRs could be responsible for
developmentofGCresistance in response toGCtreatment
of various diseases. Thus, elucidating the control of GR
levels by miRs is fundamental for understanding the eti-
ology of several proinflammatory and autoimmune dis-
orders and the associated reduced GC response, as well as
for research on cancer and neurological conditions, such
as anxiety and depression.
III. Splice Variants and Isoforms of GR
The traditional view that GCs exert their functions by
binding to one single GR protein has changed during re-
cent years after identification of several GR isoforms (Fig-
ure 2). These subtypes are the result of alternative pro-
cessing of the primary mRNA in terms of splicing and
translation. The isoforms differ in their expression pat-
terns, gene regulatory networks, and other functional as-
pects. Furthermore, differential post-translational modi-
fications (PTMs) increase the variety of GR subtypes even
more.
A. Alternative mRNA splicing
Alternative splicing near the 3 UTR of the primary
hGR transcript generates two isoforms (hGR andhGR)
differing at their C termini. The classical hGR protein
contains the end of exon 8 joined to exon 9, whereas in
the splice variant hGR, which results from an alternative
splice acceptor site, exon 8 is joined to the more down-
stream exon 9 (65–67). These two isoforms share iden-
tical amino acids up to position 727. The C-terminal ends
differ: hGR contains an extra 50 amino acids, resulting
in a protein of 777 amino acids, whereas hGR contains
15 additional amino acids and hence is composed of 742
aminoacids.Hence, hGRhas a shortened ligand-binding
domain (LBD) that cannot bindGCs.Nevertheless hGR,
which is constitutively found in the nucleus, is transcrip-
tionally active. The GR antagonist mifepristone (RU486)
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Figure 2.
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Figure 2. Splice variants and isoforms of GR. A, Genomic structure of the hGR gene. B, Alternative hGR pre-RNA slicing. C, Alternative hGR mRNA
splicing; black triangles depict deletions. D, Alternative hGR translation initiation. E, Structure of the hGR protein.
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can bind to it (68), but the endogenous ligand is currently
unknown. Genome-wide expression analyses have shown
that hGR can directly induce and repress a large number
of genes that are not controlled by GR (65, 68, 69). By
recruitment of histone deacetylase corepressors, hGR
canmediate transcriptional repression (71). In addition to
this intrinsic gene regulatory profile, transcriptional reg-
ulation by hGR can also depend on its hGR antago-
nism. Indeed, when coexpressed with hGR, hGR can
function as a dominant negative splice variant of hGR,
inhibiting its activity (72–74). In thisway, hGR can cause
GC resistance. Indeed, several reports prove the contribu-
tion of hGR to many diseases and to resistance to GC
therapies (34). For example, bronchiolitis patients in-
fected with respiratory syncytial virus showed an increase
in GR expression correlating with disease severity (75).
Moreover, elevated GR levels were found in a variety of
GC-resistant disorders, such as asthma, rheumatoid ar-
thritis (RA), and inflammatory bowel disease (76–78).
In addition, increasedGR levels also contribute to the
development of erythrocytosis in patients with polycythe-
mia vera or eosinophilic chronic rhinosinusitis (79, 80). It
was initially believed that GR is found only in humans,
but a recent report illustrated the existence of GR in
mouse (mGR) and rat as well as its prominent role in
metabolism. Although mGR arises from differential
splicing using intron 8 rather than exon 9 as in humans, it
is similar in structure and functionality to its counteriso-
form, hGR (81, 82).
Additional hGR isoforms resulting from alternative
splicing have been identified: 1) hGR, a widely expressed
splice variant, which includes an insertion of a single ar-
ginine residue between the two zinc fingers in the DNA-
binding domain (DBD) (83–85); 2) hGR-A, lacking exons
5 through 7 (86, 87); 3) hGR-P, a truncated isoformmiss-
ing exons 8 and 9 (86, 87); 4) hGR (hGR313–338), a
splice variant with a deletion in exon 2; 5) hGR-S1, re-
taining intronHbetween exons8 and9 (88); 6) hGR-NS1,
a variant containing three nonsynonymous single-nucle-
otide polymorphisms; and 7) hGR-DL1, a truncated iso-
form due to a single nucleotide deletion in exon 2. The
latter three were identified only recently (89). hGR and
hGR bind GCs and DNA with similar affinities. How-
ever, the ability of hGR to stimulate GRE reporters is
compromised, and so it has a different transcriptional pro-
file from the classical GR isoform (83, 84). Moreover,
GR expression has been associatedwithGC resistance in
small-cell lung carcinoma, corticotrope adenomas, and
childhood acute lymphoblastic leukemia (83, 84, 90).
Little is knownaboutGR-A, but studies onGR-Pprovide
evidence for its expression in several tissues. Furthermore,
GR-P seems to be the predominant GR subtype in several
GC-insensitive cancer cell types (86, 87, 91). Next,
hGR313–338 or hGR is expressed in several tissues, such
as lung, sc adipose tissue, liver, skin, heart muscle, and hip-
pocampus. Interestingly, the deleted region has a number of
potential phosphorylation sites important for the transacti-
vationpotentialofhGR.Therefore, itwas suggested that this
variant exhibits an altered GC-induced transactivation pro-
file (92). hGR-S1 has an early termination site due to the
preservation of the last intron, which contains a stop codon.
Hence, this splice variant gives rise to a truncated protein of
745 amino acids and has a lower transactivation potential
than the classical GR isoform, probably due to weaker li-
gand binding (88). Also, little is known about the recently
identifiedhGR-NS1andhGR-DL1.However, theactivityof
hGR-NS1 is at least double that of hGR, whereas the ac-
tivity of hGR-DL1 is only 10%of the activity of hGR (89).
These latter three isoformshavenotbeen linkedwith inflam-
matory disorders or GC-resistant diseases (Figure 2).
B. Alternative translation initiation
The complexity of GR biology is complicated even fur-
ther by alternative translation initiation. The eight alter-
native initiation sites (AUG start codons) in exon 2 result
in eight hGR subtypes with truncated N-terminal do-
mains (NTDs), named hGR-A to D (A, B, C1, C2, C3,
D1, D2, and D3) (93–95). These N-terminal isoforms are
the product of both leaky ribosomal scanning and ribo-
somal shunting (94). These distinct initiation sites are con-
served in other species, such as monkey, rat, and mouse.
hGR-A forms the classical full-length hGR protein of
777aminoacids,which is generated from the first initiator
codon (methionine 1) (Figure 2).
All these hGR subtypes have tissue-specific expression
patterns that are conserved in different species. For example,
levels of the GR-C isoforms are significantly higher in the
pancreas and colon, whereas levels of GR-D are highest in
spleenand lungs.Also, levels ofGR-B arehigher than those
of GR-A in liver and thymus. These GR isoforms display
different transcriptional activities in response toGCs,with a
unique gene induction profile, and have diverse subcellular
distributions (94). For example, GR-C isoforms have en-
hanced activity, at least in the induction of proapoptotic
genes, whereas the GR-D subtypes show much lower ac-
tivity compared to hGR-A, or even none at all (96–98).
Additionally, the GR-C isoforms are also more efficient in
recruiting coactivators, including RNA polymerase II, than
theGR-Disoforms,probablyduetothevariableNTD(97).
Increasedexpression levelsof the truncatedGR-D isoforms
were reported in schizophrenic patients (99). Also, the
GR-C isoforms have a subcellular distribution similar to
that of GR-A, but they have stronger transcriptional activ-
ity, suggesting the existence of an inhibitory domain within
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the N-terminus of GR. Interestingly, it was also shown that
increased amounts of GR-C3 enhanced GR-A transcrip-
tional activity (93). Thus, depending on their inherent activ-
ities and relative expression in different tissues, the GC sig-
nals might be differentially transduced by the presence of
variant N-terminal GR isoforms.
Although it is not illustrated in Figure 2, each of the
splice variants is also expected to contain these different
translation initiation sites and hence to give rise to a sim-
ilar set of translational isoforms (30). Furthermore, the
cellular composition of GR translational isoforms is sig-
nal- and time-dependent (35). Altogether, this wide vari-
ety of GR isoforms can explain the cellular heterogeneity
and tissue-specific effects of GCs. Nevertheless, the com-
plexity and diversity of GR isoforms is far from fully ex-
plored and warrants further study.
IV. Structure of the GR Protein
The hGR (777 amino acids) is a modular protein orga-
nized into three major functional domains with distinct
functions (Figure 3). The firstN-terminal 421 amino acids
of the hGR protein are designated as the NTD. This do-
main contains the ligand-independent constitutive tran-
scriptional activation function 1 (AF1), which is required
for maximal transcriptional activation of GR (101, 102).
AF1 is rich in acidic amino acids and is important for
initiation of transcription, ie, interaction of GR with co-
regulators, chromatin modulators, and the basal tran-
scriptionmachinery (103, 104). TheNTD is themost vari-
able domain among the nuclear receptors in different
species (104, 105). The next 65 amino acids in the central
region of theGR comprise theDBD,which consists of two
highly conserved zinc fingers. These two zinc fingermotifs
tetrahedrally coordinate a zinc atom held by four cysteine
residues. Obviously, the DBD is required for its DNA-
binding specificity, but it also plays a role in GR dimeriza-
tion and interaction with cofactors or other transcription
factors, suchas c-Jun.More specifically, theDBDcontains
amino acids responsible for the binding of GR to GREs.
These amino acids are primarily found in the first zinc
finger, which contains the proximal (P) box responsible
for the site-specific recognition of GREs. In addition, the
second zinc finger in the DBD holds a specific region, the
distal (D) box, comprising five amino acids required for
GR homodimerization at the GRE (106–108). Interest-
ingly, it was shown that Jun dimerization protein-2, a
small bZIP protein known to inter-
act with the DBD of the human pro-
gesterone receptor, also interacts
with the DBD of GR. Moreover, the
Jun dimerization protein-2-GR in-
teraction induces a compact struc-
ture in the NTD/AF1 in a way that
facilitates the interaction of AF1
with coregulators and hence in-
creases the transcriptional activity of
GR (109). The DBD is separated
from the C-terminal LBD by a hinge
region encompassing amino acids
486–526.Thishinge regionprovides
GR dimers with structural flexibility
that facilitates the interaction of GR
dimerswith their respectiveGRE, di-
rected by the second zinc finger. The
LBD at the C terminus is 251 amino
acids long and is moderately con-
served among species. A ligand-de-
pendent transcriptional AF2 domain
is embedded in the LBD (110). Ad-
ditionally, the LBD also plays a role
in interactionswith (co-)chaperones,
coregulators, and other transcrip-
tion factors, and interestingly also in
GR dimerization (110, 111). Fur-
Figure 3.
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Figure 3. Structure of the GR protein. GR is composed of an NTD, a DBD consisting of two zinc
fingers, a hinge region, and a C-terminal LBD. Variation in the function of GR can be correlated
with these domains. P, proximal; D, distal.
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thermore, nuclear localization signals (NLS1 and NLS2)
are also located in the DBD and LBD, respectively (112).
In addition, a nuclear export signal of 15 amino acids is
located in the DBD between the two zinc fingers and me-
diates nuclear export of GR (113, 114). Furthermore, a
nuclear retention signal (NRS) overlaps with NLS1. The
NRS delays the nuclear export of GR and hence improves
the transcriptional activity of GR (115).
V. GR Mutations and Polymorphisms
Mutations and polymorphisms in the hGR gene are an-
other level of complexity influencing the tissue specificity
ofGCs and themolecularmechanisms ofGRaction. Poly-
morphisms in the coding and regulatory regions of
NR3C1 are associated with the response to GCs, which
may be either positive (GC hypersensitivity) or negative
(resistance) (116–119). Subsequently, genetic variation
affects the success of GC therapy and disease pathology
(120). Numerous pathological mutations have been iden-
tified in the human NR3C1 gene (116, 117, 121–124).
Elucidating themechanisms and effects of thesemutations
can provide more insights into the molecular mechanisms
ofhGRactivity andcontribute todevelopmentofGCther-
apy for a wide variety of diseases. For an overview of the
known mutations in the hGR gene and their effects, see
Table 1 (only the mutations linked with a detected phe-
notype are listed). However, the most extensively studied
mutations will be described more thoroughly, namely the
BclI, N363S, and ER22/23EK polymorphisms.
Polymorphisms in theNTDofGRhavebeen associated
with variations in its mRNA levels and in its function,
generally leading to increasedGR transcriptional activity.
It is known that the NTD, containing a transactivation
domain, forms a helix upon binding with transcription
factors, such as TBP (TATA box binding protein) (125),
and mutations that affect helix formation can influence
the transactivation activity (126). Hypothetically, a
change in hydrophobicity in the NTD might alter the po-
tential to interact with coregulatory proteins and in this
way impact the transcriptional activity of GR. For exam-
ple, the N363S polymorphism, located in the NTD, is as-
sociated with increased sensitivity to GCs (127, 128). Pa-
tients carrying this mutation have a higher body mass
index (129), lower bone mineral density, obesity (129–
133), bronchial asthma (134), bilateral adrenal inciden-
talomas (135), type 2 diabetes (136), and coronary artery
disease (132). Like BclI carriers, patients carrying the
N363S mutation also have a lower risk of developing RA
(137). Generally, mutations resulting in increased GR
transcriptional activity lead to an increased risk for met-
abolic side effects. On the contrary, GR insensitivity is
associated with a more favorable metabolic profile.
Two linked, single-nucleotide mutations in exon 2
cause another polymorphism: a CAG toGAAmutation in
codon 22, which does not result in an amino acid change
(glutamic acid [E]), and aAGG toAAGmutation in codon
23, which causes substitution of arginine (R) by lysine (K)
(ER22/23EK) (123, 124, 138). This polymorphism has
been reported to reduce sensitivity to GCs (128). Indeed,
decreased GR activity has been shown by reporter assays
and expression of endogenous genes (122, 139, 140).
Hence, patients carrying the ER22/23EK polymorphism
display relativeGC resistance (123). Carriers of the ER22/
23EK polymorphism have lower risks for GC-associated
side effects and therefore a lower tendency to develop type
2 diabetes or cardiovascular disease (141).Moreover, car-
riers have a lower risk of developing dementia (123, 142)
and insulin resistance (143). However, they have an in-
creased risk of developing RA (137) andmultiple sclerosis
(144).
So far, twomutations have been discovered in theDBD
(V423A and V477H), both of which negatively affect GC
signal transduction (145, 146). Because theDBD is crucial
for proper nuclear translocation, dimerization, and DNA
binding of GR (Figure 3), both mutations were described
to impair the ability of GR to translocate to the nucleus
and to bind to target GRE elements (145, 146).
Based on the important functions of the LBD, ie, ligand
binding, nuclear translocation, and coregulator binding
(Figure 3), it is clear that mutations in this domain will
affect GR function extensively. Recently, a newly discov-
ered point mutation in the LBD (V575G) was shown to
disrupt multiple steps in the GC signaling cascade, includ-
ing the affinity for the ligand, the time required for nuclear
translocation, and the interaction with the GR interacting
protein 1 coactivator, leading to decreased GC responses
(147).
Importantly, polymorphisms located outside the cod-
ing region, eg, in introns, can also influence gene regula-
tion by affecting gene splicing, transcription, and transla-
tion efficiency, or promoter activity, or by introducing a
stop codon (148). For example, the so-called BclI site,
located 647 bp downstream of exon 2, introduces a vari-
ant that cannot be cut by the BclI enzyme and is associated
with GC hypersensitivity (128, 149, 150). Many studies
have linked the BclI mutation with a wide variety of dis-
orders, such as hypertension, adiposity, obesity (133,
151–153), and bulimia nervosa (154). Furthermore, BclI
carriers are at risk of post-traumatic stress disorder (155),
bronchial asthma (156), Crohn’s disease (157, 158), car-
diovascular disease (159), cystic fibrosis (160), obstruc-
tive airway disease (161), and atherosclerosis (153). In
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contrast, carriers are less likely to develop RA (137) and
osteoporosis (162).
Furthermore, variations in the 3 UTR region can in-
fluence the ratio of different GR splice variants because
hGR and hGR are generated by alternative splicing of
the C-terminal exon 9 (48, 67). It has been reported that
an A to G change at the first A in the ATTTA sequence
resulted in stabilization of hGR mRNA and conse-
quently increased hGR protein expression (76). This re-
sults in excess heterodimerization with hGR and may
reduce GR transcriptional activity (163). This might ex-
plain the increased risk of humans carrying this mutation
for immune-regulated pathologies, such asmyocardial in-
farction and cardiovascular disease (164).
VI. Post-translational Modifications of the
GR Protein
The above-mentioned transcriptional and post-transcrip-
tional regulation of GR illustrates the remarkable com-
plexity of GR signaling. Although tissue specificity is de-
termined primarily at the transcriptional level, each
Table 1. Mutations in the NR3C1 Gene Observed
in Humans
Polymorphism
GC
Sensitivity Increased Risk Refs.
BclI Increased Hypertension
Obesity
Bronchial asthma
Crohn’s disease
151, 152,
156, 158
N363S Increased Obesity
Bronchial asthma
Type 2 diabetes
Coronary artery
disease
131–134,
136
ER22/23EK Decreased Rheumatoid
arthritis
137, 144
Multiple sclerosis
2314InsA Decreased Lupus nephritis 260
A3669G Decreased Primary
myelofibrosis
80, 261,
262
Diamond-blackfan
anemia
TthIII I (together with
ER22/23EK)
Decreased Multiple sclerosis 144
A214G Decreased Septic shock 263
D401H Increased Hypertension 117
Diabetes mellitus
Accumulation of
visceral fat
V423A Decreased Generalized GC
resistance
145
R477H Decreased Generalized GC
resistance
146, 264
Hirsutism
Fatigue
Hypertension
T504S Increased Atopic dermatitis 260
T556I Decreased Generalized GC
resistance
265
Adrenocortical
adenoma
I559N Decreased Cushing’s disease 266–268
Hypertension
Oligospermia
Infertility
V571A Decreased Generalized GC
resistance
266, 269
V575G Decreased Hypertension 147
Hypokalemia
Oligoamenorrhea
Generalized GC
resistance
612 Decreased Familial GC
resistance
270
D641V Decreased Generalized GC
resistance
266, 271,
272
Hypertension
Hypokalemic
alkalosis
S651F Decreased Atopic dermatitis 260
G679S Decreased Clinical GC
resistance
146, 264,
273
Hirsutism
Fatigue
Hypertension
(Continued)
Table 1. Continued
Polymorphism
GC
Sensitivity Increased Risk Refs.
A714Q Decreased Generalized GC
resistance
274
Hypoglycemia
Hypertension
Clitoromegaly
V729I Decreased Generalized GC
resistance
266, 275
Precocious
puberty
Hyperandrogenism
F737L Decreased Hypertension 276
Hypokalemia
I747M Decreased Generalized GC
resistance
70, 266
Cystic acne
Hirsutism
Oligo-amenorrhea
L753F Decreased Steroid resistant
acute
lymphocytic
leukemia
100
L773P Decreased Generalized GC
resistance
250, 252
Fatigue, anxiety
Acne
Hypertension
F774S Decreased Hypoglycemia 252
Hypertension
Fatigue
9 Decreased Rheumatoid
arthritis
137
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isoform is subject to various PTMs, such as phosphory-
lation and SUMOylation. These covalentmodifications of
GR (Figure 4) affect its stability, subcellular localization,
transcriptional activity, and interaction with other pro-
teins. The modifications and their sites on the GR protein
have been extensively studiedduring the past twodecades.
A. Phosphorylation
The most common and best understood form of GR
PTM is phosphorylation, which is the reversible attach-
ment of a phosphate group to a protein, preferentially to
serine (Ser) and/or tyrosine (Tyr) residues. GR was iden-
tified as a phosphoprotein more than two decades ago
(165–170). The reversible phosphomodulation of GR is
involved in modulating and fine-tuning the GC response.
Phosphorylation of GR can affect GR ligand- and DNA-
binding affinity, subcellular trafficking, and cofactor re-
cruitment, culminating in altered transcriptional re-
sponses of GR, and consequently leading to a modified
anti-inflammatory potential (171).
Phosphorylation is regulated by the balance between
phosphorylating targeted kinases and dephosphorylating
phosphatases. Six kinases that phosphorylate hGR have
been identified: 1) the cyclin-dependent kinases (CDKs)
(172–174); 2) the p38 MAPKs (175); 3) the c-Jun N-ter-
minal kinases (JNKs) (176, 177); 4) the glycogen synthase
kinase 3 (GSK-3) (178, 179); 5) the ERK (172); and 6)
casein kinase II (172). Several phosphatases that revert the
phosphorylation have also been identified, including PP1,
PP2a, and PP5 (180). These phosphatases are involved in
the nuclear import of the ligand-activated GR (181–183).
Numerous phosphorylation sites on the hGRhave been
identified during recent years, including Ser113, Ser134,
Ser141, Ser203, Ser211, Ser226, and Ser404, most of
which are located in the AF1 domain in the NTD (172).
These residues are conserved in homologous regions of
other species, such as rat and mouse (184). The first
identified residues showing enhanced phosphorylation
in response to GCs are Ser203, Ser211, and Ser226
(185). In addition, mass spectrometric analysis of hGR
has identified other potential phosphorylation residues,
ie, Tyr8, Ser45, Ser234, and Ser267 (186). However, it
is still unknown whether these residues are actually
phosphorylated.
Which kinases phosphorylate certain residues on the
GR protein is not entirely known. Also, no GR-targeting
phosphatases have been linked to specific GR residues so
far. However, several studies have linked target residues
with the executing kinase. For example, p38 has been
shown to specifically phosphorylate Ser211, enhancing
transcriptional and apoptotic activity (187, 188). More-
over, the site-specific phosphorylation of Ser211 by p38
leads to a modified, functionally active conformation of
the AF1 domain that facilitates GR interaction with co-
regulators and enhances subsequent GR transcriptional
activity (189). However, when this Ser211 is targeted by
other kinases, such as ERK and JNK, the transcriptional
activity of GR is counteracted, compared to p38-induced
phosphorylation of Ser211 (188). Ser211 has also been
shown tobea target forCDK5 (27), but theoutcomeof the
interaction is not clear (173). These data suggest that the
effects of phosphorylation on GR activity are strongly de-
pendent on the executing kinase. Ser203 has been shown
to be the target of CDKs (A-CDK2, A-CDC2, B-CDK2,
B-CDC2, and E-CDK2) and ERK kinases (190). Phos-
phorylation of Ser203 is required but is not sufficient for
full GR activity because simultaneous phosphorylation of
Ser211 is also required (191). Although the phosphoryla-
tion of Ser203 and Ser211 primarily enhances the tran-
scriptional activity of GR, phosphorylation of Ser226 has
been shown to decrease the activity, mainly by promoting
the nuclear export of GR. Ser226 can be phosphorylated
by JNKs and CDK5 (173, 176, 187, 192). Phosphoryla-
tion of Ser404 has been associated with GSK-3, and it
leads to inhibition of GR activity due to increased nuclear
export (178).
More recently, a newhormone-independent phosphor-
ylation site, Ser134, was identified on the hGR; this site
had already been picked up bymass spectrometry analysis
(186). Phosphorylation of Ser134 is induced by the p38
MAPK in response to different stres-
sors and by AKT (193). Further-
more, due to phosphorylation of
Ser134, the GR shows increased as-
sociation with the -isoform of the
14–3–3 class of signaling protein
(14–3–3), hence leading to in-
creased transcriptional activity of
GR (194). Binding of GR to 14–3–3
	 is also known to enhance GR tran-
scriptional activity (195), but
whether this interaction also re-
Figure 4.
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Figure 4. Post-translational modifications of the GR protein. General structure of the GR protein.
Variation in the structure and function of the protein is partly caused by post-translational
phosphorylation (P), SUMOylation (S), ubiquitination (U), oxidation (O), and acetylation (A). The
asterisks refer to potential P-sites that have not been experimentally confirmed.
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quires prephosphorylation of GR on Ser134 needs further
investigation.
The phosphorylation status of GR has been linked to
several disease states. For example, p38 MAPK has been
shown to be active in alveolar macrophages of GC-resis-
tant asthma patients (196). The Ser residue that is phos-
phorylated by p38 has not been identified, but specula-
tions point to residue Ser211 or Ser226 (175, 188, 197,
198). Additionally, the phosphorylation status ofGR, and
specifically the MAPK-mediated abnormal phosphoryla-
tion of GR resulting in blunted GR activity, has been
linkedwith disordersmost often treatedwithGCs, such as
leukemia, Crohn’s disease, and asthma (197, 199, 200).
On the other hand, overactivation of GR by increased
phosphorylation at Ser211 has been linked with bipolar
disorder, a severe mental illness (201).
Overall, it is clear that phosphorylation of GR has a
major effect on its activity, suggesting that the GR phos-
phorylation status plays a critical role in the effectiveness
of GC treatments. However, the concurrent phosphor-
ylation sites and the accompanying kinases determine
the specific outcome. For example, evidence shows that
JNK-, ERK-, andGSK-3-mediated phosphorylation of
GR blunts GR activity. These findings suggest that the
concomitant administration of inhibitors for these ki-
nases could abrogate the GC resistance observed in
some disease states. Conversely, full GR activity re-
quires the phosphorylation of several residues, such as
Ser211. Both p38 and CDKs have been shown to en-
hance GR activity, primarily by targeting Ser211.
Clearly, the phosphorylation of GR is another aspect of
the complexity of its signaling.
B. Ubiquitination
Ubiquitination is an important PTM process that can
be facilitated by precedent phosphorylation events and
targets GR (202). Ubiquitination is the covalent attach-
ment ofmultiple ubiquitin residues (8.5 kDa) by a series of
ubiquitin enzymes (E-1 activating enzymes, E-2 conjugat-
ing enzymes, and E-3 ligases) to the target molecule. This
labeling targets the protein for further processing, eg, pro-
teasomal degradation by the 26S proteasome. E-2 and E-3
ubiquitin enzymes recognize a specific sequence on their
target proteins, namely the PEST sequence (proline, glu-
tamic acid, serine, threonine) (203, 204).
Ubiquitination and subsequent proteasomal degrada-
tion control the turnover of GR, and hence its tran-
scriptional activity (205, 206). Furthermore, ubiquiti-
nation also increases the mobility of GR in the nucleus
(206). This negatively affects the activity of GR due to
induced GR export. Ligand-activated hGR becomes
ubiquitinated (K48-linked on residue lysine 419); this
lysine is located in the degradation PEST motif in the
NTD of GR (207).
GR interacts physically with the E-2 enzyme, UbcH7.
Overexpression of UbcH7 reduces the transactivation po-
tential ofGR,whereas inhibitionof the26Sproteasomeby
MG132 abolishes this reduction (208). GR is also regu-
lated by three different E-3s, namely carboxy terminus of
Hsp70-interacting protein (209, 210), ET-AP (210), and
the human homolog of mdm2 (hmdm2) (211). Hmdm2
functions by generating a trimeric complex together with
p53 (212).
Although ubiquitination can be cell-type specific, all
known GR isoforms contain the target residue K419 and
hence are subject to ubiquitin-mediated proteasomal
degradation.
C. SUMOylation
Another PTM that can regulate GR function is SU-
MOylation, which is the addition of a small ubiquitin-
related modifier-1 (SUMO-1) (213). SUMO-1 is a mol-
ecule of 11 kDa that is covalently attached to lysine
residues of the target protein. Although SUMO-1 re-
sembles ubiquitin in size and structure, SUMOylation
does not directly target proteins for proteasomal deg-
radation; it affects protein stability, protein–protein in-
teractions, subcellular localization, and transcriptional
activity (214, 215).
The hGR protein is thought to include three SUMOy-
lation sites:K277,K293, andK703 (216).Overexpression
of SUMO-1 destabilizes GR, but this can be reversed by
inhibiting the proteasome. Furthermore, SUMO conju-
gaseUbc9 physically interactswithGR (217, 218). In con-
trast, a stimulatory effect of SUMOylation on the tran-
scriptional activity of GR has also been reported (213).
This might be due to SUMO affecting GR in a promoter-
and cell-specific manner. However, a recent report dem-
onstrates the interaction of RWD-containing SUMOyla-
tion enhancer (RSUME) with GR, which would increase
its SUMOylation. RSUME positively regulates the tran-
scriptional activity of GR by targeting K703, whereas tar-
geting the other residues has a negative effect. Thus, the
presence of both positive and negative SUMO-target sites
in the GR could account for the conflicting data reported
earlier (219). These SUMOylation sites have recently been
shown to regulate the chromatin occupancy of GR on
several loci.More specifically, SUMOylation seems to reg-
ulate GR activity in a target locus selective manner (220).
Interestingly, SUMOylation of GR could also be inter-
preted as a phosphorylation-mediated event because
phosphorylation of GR Ser226 by JNK facilitates the SU-
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MOylation of GR at its N-terminal SUMOylation target
sites (221).
D. Acetylation
GR protein function is also under the control of acet-
ylation. Although enzymes involved in (de-)acetylation
events, ie, histone acetyltransferases and histone deacety-
lases (HDACs), primarily target the lysines located in hi-
stone tails, there is evidence for direct acetylation of other
proteins, notably GR.
Beforenuclear translocation,GCs induce acetylationof
GR at K494 and K495, located in the hinge region (176).
A more recent report points to acetylation of a cluster of
lysines in the hinge region by the circadian rhythm-gen-
erating transcription factors CLOCK and BMAL1,
thereby diminishing the transcriptional activation of a
GRE reporter by GR (222). Moreover, to interact with
NFBand repress inflammation,GRmust be deacetylated
by HDAC2 (176). Several studies have shown that over-
expression of HDAC2 is involved in the reversal of GC
resistance in patients with chronic obstructive pulmonary
disease and asthma (223–227). We speculate that hyper-
acetylation ofGR in the absence ofHDAC2or due to high
levels of CLOCK and BMAL1 leads to GC insensitivity in
patients.
E. Nitrosylation
Nitrosylation has been reported to affect GR activity.
Several critical cysteines, which are necessary for ligand
binding, are located in the DBD and LBD of GR (226,
228). Generally, cysteines contain sulfhydryl groups,
which are extremely prone to react with nitric oxide (NO)
to form S-nitrosothiols. Besides the early identification of
Cys656asoneof the first aminoacids tobemodifiedof the
GR (229), no additional specific cysteines have been des-
ignated to be targeted by nitrosylation. Nevertheless, the
use of NO donors could decrease the binding of GR to its
ligand, and this binding could be inhibited by the thiol-
protecting agent dithiothreitol (230). Moreover, NO in-
terferes with the GR-mediated anti-inflammatory effects
of GCs. Therefore, nitrosylation of critical sulfhydryl
groups in GR by NO could be the reason for GC insensi-
tivity of septic shock patients, who have higher levels of
NO (226). Next, inhibiting neuronal NO synthase in the
hippocampus increased GR expression, indicating that
neuronal NO synthase is an inhibitor of GR expression in
the hippocampus, and therefore a potential modulator of
the entire hypothalamic-pituitary-adrenal gland-axis cas-
cade (231, 232).
However, the effect ofNOonGRactivity remains con-
troversial.Other studies have reported thatGRexpression
is up-regulated by NO and suggested that GC therapy
could be more effective in combination with NO (233).
Furthermore, exogenous NO has been shown to activate
the endothelial GR, and specifically its nuclear transloca-
tion and the transactivation of reporter constructs (234).
In addition, GR-mediated limitation of inflammation
could be potentiated by a NO-donating prednisolone de-
rivative, NCX-1015. This was assessed by augmented
binding to its ligand, nuclear translocation, and the rapid
inhibition of neutrophil recruitment in a model of perito-
nitis (235). Obviously, the effect of nitrosylation on the
GR protein, whether it is stimulatory or inhibitory, re-
quires more in-depth investigation.
F. Oxidation
Studies have shown that the functional activity of GR
can be suppressed by oxidative conditions and restored in
the presence of reducing agents (236, 237). Oxidation is
closelyassociatedwithnitrosylationbecause it alsomainly
targets sulfhydryl groups. Cysteine 481 (Cys481) in par-
ticular seems to be a target for oxidation because its sub-
stitution reduced the sensitivity of GR to oxidative treat-
ments, such as H2O2. Modification of GR by oxidation
has been shown to reduce ligand binding and subsequent
DNA binding activity of GR. Reducing agents, such as
dithiothreitol or N-acetyl-L-cysteine, and the overexpres-
sion of thioredoxin reductase, effectively counteract the
negative effect of H2O2 (169, 226, 236, 238–241). Oxi-
dative stress can also indirectly influence GR function by
decreasing the expression and activity of HDAC2, which
has been linked with GC insensitivity in asthma patients
(223, 242).
VII. Role for DNA Binding Sequences in
Directing GR Conformation and Function
GR binding sequences (GBSs) are abundant in the mam-
malian genome (Figure 5). However, recent genome-wide
ChIPseq analyses have shown that only a fraction of the
GBSs are bound by GR (243–245). These sequences are
typically imperfect palindromic hexamers separated by a
3-bp spacer. The first hexamer consists of five positions
that are nearly identical in different species and among the
promoters of different GR-inducible genes (246). The
spacer and second hexamer are less conserved. Recent re-
search indicates an important, formerly unidentified, role
for theDNAbinding sequence in instructingGR-mediated
transcriptional activation. The first evidence came from
Meijsing et al (85), who illustrated that the DNA binding
sequence forms an allosteric ligand with GR, directing
minor but important changes in the receptor’s structure
and hence in transcriptional activity. That study demon-
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strated that GBSs use GR surfaces, ie, the AF1 and AF2
domains and the dimerization loop (D box) in theDBD, in
differentways. For example,GBSswith identical half-sites
but different spacers direct the different usage of these
three GR surfaces. Interestingly, a crucial role was de-
scribed for the “lever arm,” a domainwithin theDBD that
connects theDNA-binding loop (Pbox)with thedimeriza-
tion loop (D box). This observation was supported by a
recent study byWatson et al (108), who provide evidence
that the interaction with bases at particular positions in
the binding sequence, such as in the first half-site or in the
spacer region, directs the conformation of these distinct
GRregions.Theauthors suggested that theDNAsequence
tailors the conformation of the lever arm. Extra evidence
for the crucial role of the lever armwas provided by using
the DBD of the GR isoform, which has an extra arginine
residue in the lever arm.This isoformand theGR isoform
up-regulate different sets of genes. The DNA occupancy
and structures, however, were comparable for both iso-
forms, suggesting that the lever arm directs gene-specific
events after GR-DNAbinding and transmits the signals to
other GR domains (85). More recently, it was demon-
strated that the selection of GR binding regions by the
GR isoform and the subsequent downstream events are
directedby the insertion in the lever
arm (108, 247). Furthermore, it was
suggested that the lever arm of GR
mediates bidirectional allosteric sig-
naling. DNA sequence selectivity is
translated into conformational
changes in the DBD, more specifi-
cally the D-loop, and changes in the
dimerization domain affect other
GR surfaces that can interact with
cofactors (247). Proof of concept has
beenprovidedbymutating the dimer
interface, which resulted in an al-
tered sequence-specific conforma-
tion of GR, DNA-binding kinetics,
and transcriptional activity. More-
over, itwas illustrated thatGRdimer
partners collaborate to interpret the
DNA shape and sequence in order to
direct the sequence-specific gene
transcriptional activity of GR (108).
In conclusion, GBSs seem to direct
the structural changes at the DNA
binding interface,which is translated
by the lever arm to the dimerization
interface and GR dimer partners,
and hence results in differential tran-
scriptional outcomes. The mecha-
nism regulating DNA-binding kinetics and the effects on
the transcriptional outcome of GR remains to be eluci-
dated.However, it has beenproposed that thewidth of the
minor groove might act as an indirect readout of spacer
sequence (108).
A crucial role has also been shown for the nGRE con-
sensus sequence,CTCC(N)0–2GGAGA, in controllingGR
binding orientation and dimerization (248). These so-
called negative GREs were thoroughly described by Surjit
et al (249) and shown to be present in over 1000 mouse/
human orthologous genes. GR monomers occupy the
DNA half-sites of these nGREs, but they do not ho-
modimerize (248). Moreover, it was suggested that these
nGREs affect the conformation of some critical GR resi-
dues, which are critical for transcriptional activation,
hence resulting in repression instead of activation (248).
Hence, these findings support the observation that DNA
is an allosteric modulator of GR activity. Overall, the
above-mentioned findings show that the DNA sequence
acts as a modulator affecting the interaction of GR with
DNA and cofactors by directing conformational changes
in its dimerization interface, and hence directing the tran-
scriptional outcome.
Figure 5.
Figure 5. DNA binding sequence directs GR structure. General overview of the GR protein
binding to its GRE, zoomed in on the DBD. a, Upon binding to the first half-site (yellow box), the
spacer sequence (gray box) directs the conformation of the lever arm. b, The lever arm
subsequently translates this information to the D-loop in the DBD. c and d, The DBD
conformation directs the structure of both the LBD and NTD, respectively. e and f, This further
influences the interactions with cofactors and other partner, and hence the transcriptional
outcome of GR signaling.
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VIII. Future Perspectives and Therapeutic
Implications
GCs are widely used to treat many inflammatory condi-
tions, but the outcome varies considerably among pa-
tients. This variation can be attributed to the presence of
different GR isoforms with unique expression and gene
regulatory profiles or different polymorphisms in the hGR
gene. The recent finding that the GR-bound DNA se-
quence acts as an allosteric ligand directing the activity of
GR can also account for the gene-, tissue-, and individual-
specific effects observed. Furthermore, not only the DNA
sequence, but also epigenetic regulators, context, and
other unrecognized regulatory factors can influence the
transcriptional outcome, hence complicating the picture
of GR function and regulation. However, development of
new revealing techniques, such as ChIPseq and nuclear
magnetic resonance, will help uncover the genome-wide
profiling of cistromes and the structural biology of tran-
scription factors (14, 15, 108, 247, 251). Hence, deter-
mining the presence of these hGR variants and regulatory
factors in a patient is critical for optimizing GC dose for
maximal therapeutic efficacy andminimal side effects. To
develop personalized GC-based therapy, future research
should also focus on the processes that mediate the gen-
eration of GR splice variants and translational isoforms.
Obviously, the research community still lacks detailed
knowledge on the mechanisms of GR structure and func-
tion. Structural and functional studies of other nuclear
receptors could also help us to look at GR from a new
angle (reviewed in Ref. 253).
ReducedGCsensitivity canalsobe causedby thepatho-
physiological processes. It is well known that a proinflam-
matory environment can negatively affect GR function in
many ways (254, 255). Because various cell types and cy-
tokines are involved in the pathogenesis of inflammatory
diseases, the mechanisms contributing to decreased GC
sensitivity in any particular disease are heterogeneous.
However, the mechanisms of reduced GC responsiveness
are not well understood, although numerous mediators
have been identified. For example, next to the critical role
for miRs, a role for small noncoding RNAs was recently
revealed.NoncodingRNAGas5, which is associatedwith
growth arrest and starvation, was shown to repress GR
transcriptional activity. Gas5 can bind specifically to the
DBD of GR by acting as a decoy GRE, and thereby com-
pete with GR for binding to its GREs (256). Thus, a more
detailed understanding of the molecular mechanisms of
GR function may reveal new drug targets that could be
exploited to sensitize resistant diseases to the anti-inflam-
matory effects of GCs. Furthermore, cell or tissue-based
therapies could be used, such as GCs delivered in lipo-
somes, topical applicationofGCs, and targeteddelivery to
the colon of dextran and sulfonate conjugates (257–259)
to increase GC effectiveness and reduce potential adverse
side effects. A combinatory therapeutic approach can also
be considered. GCs could be combined with a substance
inhibiting a PTM of GR. Such a substance could be a
downstreammolecule of the signaling pathway of various
cytokines because there is an intricate interplay between
GR and cytokines, such as TNF and IL-1 (reviewed in
Refs. 254 and 255). The use of such combined approaches
should allow the use of lower doses of GR ligands, which
would reduce the side effects and increase sensitivity. Fi-
nally, the current and future findings on GR function
should be translated to the clinic to ensure more effective
and safer GC therapies.
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